Yuk Ting Ma

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Daniel H. Palmer · 6 shared papers, 2017–2025 · strength 0.54
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pan… DOI 10.18632/oncotarget.18879↗
2. Juan W. Valle · 5 shared papers, 2017–2025 · strength 0.46
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. DOI 10.1016/j.pan.2018.10.003↗
3. Paula Ghaneh · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
4. Paul J. Ross · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
5. Thilo Hackert · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
6. John P. Neoptolemos · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
7. David Cunningham · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
8. Harpreet Singh Wasan · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
9. Christopher Michael Halloran · 4 shared papers, 2017–2025 · strength 0.39
   • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
10. Keith John Roberts · 3 shared papers, 2020–2023 · strength 0.35
    • Paper Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A S… DOI 10.1097/mpa.0000000000001694↗
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic… DOI 10.1111/ans.16643↗
11. Christoph Springfeld · 2 shared papers, 2023–2025 · strength 0.29
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
12. Gary Middleton · 3 shared papers, 2017–2025 · strength 0.27
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
13. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
14. Bengt L. G. Glimelius · 3 shared papers, 2017–2025 · strength 0.27
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
15. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
16. Pascal R. Hammel · 3 shared papers, 2017–2025 · strength 0.27
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
17. Nikolaos A. Chatzizacharias · 2 shared papers, 2020–2021 · strength 0.23
    • Paper Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A S… DOI 10.1097/mpa.0000000000001694↗
    • Paper Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic… DOI 10.1111/ans.16643↗
18. Pankaj Punia · 2 shared papers, 2018–2021 · strength 0.23
    • Paper Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series. DOI 10.1159/000488139↗
    • Paper Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic… DOI 10.1111/ans.16643↗
19. Markus Wolfgang Büchler · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
20. Derek A O'Reilly · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
21. Salma Moona Alam · 2 shared papers, 2018–2019 · strength 0.19
    • Paper Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series. DOI 10.1159/000488139↗
    • Paper Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. DOI 10.1016/j.pan.2018.10.003↗
22. Peter J. Bailey · 1 shared paper, 2025 · strength 0.17
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
23. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.17
    • Paper Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. DOI 10.1200/jco.24.01118↗
24. Joseph Anthony Attard · 1 shared paper, 2020 · strength 0.12
    • Paper Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A S… DOI 10.1097/mpa.0000000000001694↗
25. Iain Stephen Tait · 1 shared paper, 2023 · strength 0.12
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.